The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 1, 1998, Pages 65-72

  Ladner, S K ^a   Miller, T J ^a   Otto, M J ^a   King, R W ^a,b  

^a Avid Therapeutics Inc   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

3TC; Drug resistance; Hepatitis B virus; Lamivudine

Indexed keywords

DNA POLYMERASE; LAMIVUDINE; NUCLEOSIDE ANALOG; TETRACYCLINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURAL GENE;

ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; DRUG RESISTANCE, MICROBIAL; HEPATITIS B VIRUS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; TETRACYCLINE; VIRUS REPLICATION;

EID: 0031974697     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Shiff ER & Brown NA (1997) Hepatitis B virus resistance to lamivudme given for recurrent infection after orthotopic liver transplant. Lancet 349:20-22.
2. Deinstag JI, Perrillo RP, Schiff ER, Bartholomew M, Vicary C & Rubin M (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine 333:1657-1661.
3. Fallows DA & Goff SP (1995) Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. Journal of Virology 69:3067-3073.
4. Fischer KP & Tyrell DLJ (1996) Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis winch demonstrates resistance to lamivudine [(-)-(-L-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrobial Agents & Chemotherapy 40:1957-1960.
5. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C & Wainberg MA (1993) The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents & Chemotherapy 37:1390-1392.
6. Gossen M & Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proceedings of the National Academy of Sciences, USA 89:5547-5551.
7. Grellier L, Muimer D, Ahmed M, Brown D, Burroughs AK, Tolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E & Dusheiko G (1996) 3TC prophylaxis against reinfection in liver tansplantation for hepatitis B cirrhosis. Lancet 348:1212-1215.
8. Gu Z, Gao Q, Li X, Parniak MA & Wainberg MA (1992) Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. Journal of Virology 66:7128-7135.
9. King RW, Garber S, Winslow DL, Reid C, Bacheler LT, Anton E & Otto MJ (1995) Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chemistry Chemotherapy 6:80-88.
10. Knowles BB, Howe CC Aden DP (1980) Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497-499.
11. Ladner SK, Otto MJ, Barker CJ, Zaifert K, Wang G-H, Guo J-T, Seeger C & King RW (1997) Inducible expression of human hepatitis B virus DNA in Chinese hepatitis Bvirus in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrobial Agents & Chemotherapy 41:1717-1720.
12. Lai C-H, Ching C-K, Tung AK-M, Li E, Young J, Hill A, Wong BC-Y, Dent J & Wu P-C (1997) 3TC is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
13. Lanford RE, Notvall L & Beames B (1995) Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. Journal of Virology 69:4431-4439.
14. Ling R, Mutimer D, Ahmed M, Boxall E, Elias E, Dusheiko M & Harrison TJ (1996) Selection of mutations in the hepatitis B virus poylmerase during therapy of transplant recipients with 3TC. Hepatology 24:711-713.
15. Mellors JW, Larder BA & Schinazi RF (1995) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. International Antiviral News 3:8-13.
16. Otto MJ, Garber S, Wnslow DL, Reid CD, Aldrich P, Jadhav PK, Patterson CE, Hodge CN & Chen Y-SE (1993) In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proceedings of the National Academy of Sciences, USA 90:7543-7547.
17. Quan Y, Gu Z, Li X, Li Z, Morrow CD & Wainberg MA (1996) Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. Journal of Virology 70:56442-5645.
18. Schinazi RF, Lloyd Jr RM, Nguten M-H, Cannon DL, McMillan A, Ilkosy N, Chu CK, Liotta DC, Bazmi HZ & Mellors JW (1993) Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine analogs. Antimicrobial Agents & Chemotherapy 37:875-881.
19. Schinazi RF, Gosselin G, Faraj A, Korba BE, Liotta DC, Chu CK, Mathe C, Imbach J-L & Sommadossi J-P (1994) Pure nucleoside enantiomers of (-)2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrobial Agents & Chemotherapy 38:2172-2174.
20. Severini A, Liu X-Y, Wilson JS & Tyrell DLJ (1995) Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents & Chemotherapy 39:1430-1435.
21. Smith RA, Remington KM, Lloyd Jr RM, Schinazi RF & North TW (1997) A novel met-to-thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. Journal of Virology 71:2357-2362.
22. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM & Tyrell DLJ (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to 3TC in vitro. Hepotology 24:714-717.
23. Tisdale M, Kemp SD, Parry NR & Larder BA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 90:5653-5656.